A Single Center, Open-Label, Single-Dose, Cross-over, Bioavailability Study of MGL-3196 Tablets Compared to Capsules in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 19 Sep 2019
Price : $35 *
At a glance
- Drugs Resmetirom (Primary) ; Resmetirom (Primary)
- Indications Hyperlipoproteinaemia type IIa; Non-alcoholic steatohepatitis
- Focus Pharmacokinetics
- Sponsors Madrigal Pharmaceuticals
- 17 Sep 2019 Status changed from active, no longer recruiting to completed.
- 09 Feb 2018 Status changed from not yet recruiting to active, no longer recruiting.
- 31 Jan 2018 New trial record